YASH AGRAWAL

yash.agrawal9229@gmail.com | +1-385-443-9229 | www.linkedin.com/in/yashgrwl71 | Portfolio

SUMMARY

Results-driven Investment Analyst with an MBA and engineering background. Experienced in venture capital, medical device incubation and public markets. Contributed to investment decisions on deals totaling more than \$750K.

EDUCATION

David Eccles School of Business | University of Utah (GPA 3.8/4.0)

Salt Lake City, UT (May 2025)

- MBA & MS in Finance
- CFA Level 1

Indore Institute of Science & Technology | Rajiv Gandhi Technical University

Indore, India (May 2019)

• Bachelor of Engineering (Mechanical)

SKILLS

- Core Competencies: Business Valuation, Portfolio Management, Risk Assessment, IC Memo Writing, Team Collaboration
- Technical skills: Data Analysis, SQL, Python, Financial Analysis, Scenario & Sensitivity Analysis, Investment Return Analysis
- Software & tools: Bloomberg Terminal, Capital IQ, Pitchbook, Power BI, Tableau, PowerPoint, Microsoft Excel (Advanced)
- Certifications: Financial Modelling & Valuation Analyst (CFI)

EXPERIENCE

Investment Analyst | Student Investment Fund

Salt Lake City, UT (Aug 2024 – May 2025)

- Managed a \$1.1M student-run fund, deploying public equity and macro strategies to generate alpha and mitigate portfolio risk
- Oversaw fund accounting and reporting processes, ensuring accuracy in financial tracking and performance documentation
- Conducted fundamental analysis and valuation to drive \$73K in allocations across equity and commodity strategies, including a
 momentum model with 1030% back-tested return

Investment & Market Analyst | Center for Medical Innovation

Salt Lake City, UT (May 2024 – May 2025)

- Conducted market assessments for 10+ novel medical devices, evaluating commercial viability and presenting recommendations to leadership on opportunities with \$395M+ serviceable market
- Built a financial model to optimize deal flow and resource planning, ensuring alignment with return targets & commercialization timelines

Investment Analyst | Sorenson Impact Institute

Salt Lake City, UT (May 2024 – Dec 2024)

- Conducted due diligence, financial and impact analysis, and valuation for 6 early-stage ventures; supported IC memos, founder interviews, and investment decisions
- Participated in the end-to-end investment process, deploying \$550K across 3 startups in healthcare and edtech; independently sourced 300+ startups and screened 45+ for high-potential opportunities

Fraud Analyst | Goldman Sachs & Co

Bengaluru, India (Apr 2023 – Jul 2023)

 Conducted in-depth fraud investigations, process enhancements, and fostered cross-team collaboration to strengthen fraud prevention for Apple Cards

Fraud Analyst | Amazon.com Inc

Hyderabad, India (Jul 2019 – Apr 2023)

- Built a high-risk authorization system and new tracking metrics for Amazon Japan, cutting fraud authorization related support cases by 32% and reducing repeat ATO cases by 48%
- Handpicked to set up core processes for the Japan marketplace ops team designed 6 major and 13 minor workflows, and trained 28 investigators as part of a new advisory team to strengthen fraud compliance

DEAL EXPERIENCE

Chae Organics | \$5.75M Acquisition Opportunity | Consumer Health & Wellness

- Sourced and screened the target; led commercial & financial due diligence including market analysis, valuation, and scenario modeling
- Presented the investment thesis to 10 investors; supported a deal with 72% base case IRR and 15.2x MOIC

Zocalo Health | \$250K | Telehealth

- Conducted market, competitor, and business model analysis for a culturally tailored health care platform serving Latino communities
- Supported investment decision based on projected 11.6x CoC and 45.7% IRR, driven by payer partnerships, PMPM revenue model, and traction with MCOs covering 10M+ lives

Rebel Medicine (Alevatrix) | \$50K | Non-Opioid Pain Treatment

- Evaluated preclinical non-opioid pain therapy, analyzing regulatory path, clinical need, and alignment with post-opioid care trends
- Conducted pre-seed diligence process by benchmarking comparable and identifying adoption risks across provider networks